Anterior myocardial infarction is a critical condition with significant implications for cardiac function and patient prognosis. Despite advancements in reperfusion therapies, optimizing recovery during the early phases of myocardial infarction remains challenging. Anterior myocardial infarction can lead to substantial long-term effects on a patient’s health due to extensive damage to the heart muscle, particularly the left ventricle, impacting both quality of life and overall prognosis. Vericiguat, a soluble guanylate cyclase stimulator, has shown promise in heart failure, but its role in early anterior myocardial infarction has not yet been fully explored. By enhancing soluble guanylate cyclase activity, vericiguat may increase cyclic guanosine monophosphate production, leading to vasodilation, inhibition of platelet aggregation, and potential cardioprotective effects. Currently, treatment options for anterior myocardial infarction primarily focus on reperfusion strategies and managing complications. However, there is a critical need for adjunctive therapies that specifically target the pathophysiological changes occurring in the early phases of myocardial infarction. Vericiguat’s mechanism of action offers a novel approach to improving vascular function and myocardial health, potentially contributing to innovative treatment strategies that could transform the care and prognosis of patients with anterior myocardial infarction.

Aortic stenosis (AS) is increasingly recognized as a complex myocardial disease rather than an isolated valvular disorder. Emerging translational and clinical evidence suggests that diastolic dysfunction in AS is not merely an epiphenomenon of aging or comorbidity burden but develops early and may represent a central mechanistic link between valvular obstruction and heart failure. Chronic left ventricular pressure overload increases wall stress and myocardial oxygen demand, triggering a cascade of structural, metabolic, and microvascular alterations that culminate in left ventricular hypertrophy, interstitial fibrosis, impaired relaxation, and reduced ventricular compliance. The severity of diastolic dysfunction before aortic valve replacement significantly influences clinical outcomes. Persistent myocardial fibrosis and impaired diastolic reserve may remain despite successful valve intervention, helping explain why a substantial proportion of patients continue to experience heart failure symptoms after valve replacement. Despite its clinical relevance, diastolic dysfunction remains insufficiently integrated into current guideline-directed decision-making, raising the question of whether it should assume a more central role in determining the optimal timing of aortic valve replacement. Beyond correction of valvular obstruction alone, diastolic dysfunction may therefore represent both a marker of advanced myocardial remodeling and a potential therapeutic target in patients with AS.